Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis.

PloS one - 1 Jan 2025

Zhou Qin, Pu Na, Xu Ge, Liu Hangchi, Jia Xudong, Wang Xiaomin, Xu Peng

Abstract excerpt

BACKGROUND: The emergence of drug-resistant Tuberculosis (TB) has made treatment challenging. Although fluoroquinolones (FQs) are used as key drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB), the problem of FQs resistance is becoming increasingly serious. Rifampicin (RIF) resistance is considered a risk factor for FQs resistance. The objective of this study was to investigate the impact of RIF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to DNA Gyrase
Share to Drug Resistance, Multiple, Bacterial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluoroquinolones

Share to Isoniazid

Share to Moxifloxacin

Share to Mycobacterium smegmatis

Share to Rifampin

Source

Open in PubMed Open full text

Identifiers

PMID: 39746086
DOI: 10.1371/journal.pone.0315512
PMCID: PMC11694965

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis.PMID 39746086Read ↗

Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients.Semantic proximity Read ↗

Gemifloxacin resistance in Mycobacterium tuberculosis without QRDR mutations in gyrA or gyrB: evidence for non-canonical resistance mechanisms.Semantic proximity Read ↗

Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.Semantic proximity Read ↗

Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China.Semantic proximity Read ↗

Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.Semantic proximity Read ↗

Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.Semantic proximity Read ↗

Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.Semantic proximity Read ↗

Molecular detection of fluoroquinolone resistance-associated gyrA mutations in ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Iran and Belarus.Semantic proximity Read ↗

Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patientsSemantic proximity Read ↗

High frequency of isoniazid and fluroquinolone resistance among patients with rifampicin sensitive tuberculosis.Semantic proximity Read ↗

High Proportion of Fluoroquinolone-Resistant Mycobacterium tuberculosis Isolates with Novel Gyrase Polymorphisms and a <i>gyrA</i> Region Associated with Fluoroquinolone SusceptibilitySemantic proximity Read ↗

gyrA and gyrB gene mutation in ciprofloxacin-resistant Mycobacterium massiliense clinical isolates from Southern Brazil.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.